



FLORIDA SOCIETY OF CLINICAL ONCOLOGY FAX BLAST –September 2, 2009

FLASCO WEBSITE: www.flasco.org

FLASCO CLINICAL TRIALS NETWORK WEBSITE: www.fctn.org

MESSAGE FROM THE PRESIDENT: Gerald Robbins, MD

Business of Oncology Summit:

FLASCO will be holding its 1st Annual Business of Oncology Summit on October 3, 2009, in Tampa. FLASCO has partnered with Abraxis BioScience to hold this very exciting and timely conference. Topics that will be presented by expert speakers are as follows: Financial Planning, Managed Care Contract Negotiations, Succession Planning, Clinical Pathway Development and Implementation, Utilizations and Responsibilities of the PA/ARNP, and Strategic Planning: What, Why and How.

JOIN US for this professional forum that explores what cancer care leaders are doing to achieve a future vision of successful cancer care delivery, focusing on innovative business practices, clinical integration, and patient-centric approaches to providing care. For more information on the Business of Oncology Summit or to register, please go online to www.flasco.org. The meeting announcement and registration form are available there. **Registration deadline is September 15, 2009**

PROGRAM COMMITTEE UPDATES: Jose Lutzy, MD, Chairman

2010 PA/NP Conference:

We are pleased to announce that FLASCO will sponsor its Second Annual Conference for PAs/NPs on March 26, 2010, in Miami. Special thanks are extended to Dayne Alonso, PA-C and Michele Taffaro Neskey, PA-C for agreeing to serve as Co-Chairmen of the Workgroup to plan this Conference.

FLASCO CANCER TRIALS NETWORK UPDATE:

FCTN opened 2 new trials in August, 2009. The new trials and participating sites are:

Millenium C05009: A Randomized Phase 3b Study for Patients with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE[®] (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE[®] and Dexamethasone (VD) versus VELCADE[®], Melphalan, and Prednisone (VMP) **Site: Space Coast Medical Associates, Dr. Richard Levine**

Sanofi-aventis EFC 10261: A Multinational, Randomized, Double-blind Study Comparing Aflibercept versus Placebo in Patients Treated with Second-line Docetaxel after Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) **Site: Pasco Hernando Oncology Associates, Dr. K.S. Kumar**

In addition, Florida Hospital Cancer Institute has been added as a site for the Lilly H3E-MC-JMIG NSCLC study with Dr. Tarek Mekhail as PI.

Opening soon is a first line metastatic breast cancer study for HER2/neu positive patients (GSK) and a Phase II study patients with relapsed or refractory Hodgkin's Lymphoma (Syndax).

If you are interested in participating in any of the FCTN trials, please contact Janice Grimes at 912-258-2333.

CMS UPDATES:

Revised ICD-10-CM/PCS Bookmark

The revised *ICD-10-CM/PCS Bookmark* (August 2009), which provides information about the ICD-10-Clinical Modification/Procedure Coding System (ICD-10-CM/PCS) including the benefits of adopting the coding system,

recommended steps to be taken in order to plan and prepare for implementation of the coding system, and where additional information about the coding system may be found, is now available in print format from the Centers for Medicare & Medicaid Services *Medicare Learning Network*. To place your order, visit <http://www.cms.hhs.gov/MLNGenInfo/>, scroll down to “Related Links Inside CMS” and select “MLN Product Ordering Page.”

ASCO UPDATES:

ASCO Comments on 2010 HOPPS Proposed Rules

ASCO submitted comments on CMS’s proposed changes to the Medicare Hospital Outpatient Prospective Payment System and CY 2010 Payment Rates. In these comments, ASCO strongly advises CMS to set reimbursement for separately paid drugs and biological at ASP+6%. We disagree with CMS’s decision to package all contrast agents and diagnostic radiopharmaceuticals, and continue to believe that packaging should never include products that are part of anticancer therapeutic regimens. ASCO supports the CMS proposal to reimburse for the use of therapeutic radiopharmaceuticals using ASP information.

To access the full comments, please visit

<http://www.asco.org/ASCOv2/Department%20Content/Cancer%20Policy%20and%20Clinical%20Affairs/Downloads/2010%20ASCO%20Comments%20HOPPS.pdf>. Please send any questions or comments to publicpolicy@asco.org.

ASH UPDATES:

The ASH annual State-of-the-Art Symposium is taking place on September 11-12 in Chicago, IL. This year’s meeting is focused on advances in hematologic malignancies and platelet disorders. The direct link to the meeting site is

<http://hematology.org/meetings/sas/index.cfm>.

PA/NP UPDATES:

12th Annual APAO Conference

The APAO National Conference is scheduled for September 10-13, 2009, in Boston. The meeting is for MidLevels and Physicians . There will be an ASCO highlights on 9/10/09. You may register on-line at: <http://www.focus-ed.net/apao/>

BUSINESS Q & A: (Source: The Phipps Wealth Management Group)

Q. My tax advisor seldom suggest anything and basically is a tax return preparer. How can I get him/her to really be a TAX ADVISER?

A. We have a series of written questions and issues we can share with you to give him/her. They normally generate some action. Per your direction, we can speak with them, too.

For more information you may contact: 561-276-1635 Direct - 877-276-1635 Toll Free – fax: 561-922-3275 - E-mail: jeffrey_phippsr@ml.com - <http://fa.ml.com/PhippsGroup/>

CORPORATE MEMBERSHIP/SPONSORSHIP: (January 1 – December 31, 2009)

FLASCO Members extend a big thanks to all of our 2009 Corporate Members/Sponsors (Companies listed below have either paid 2009 dues or have submitted letters of intent)

PLATINUM

AMGEN
Bayer/Onyx
Cephalon Oncology
Eli Lilly
Oncology Supply/ION
Sanofi-Aventis
Celgene

Eisai, Inc.
Ortho Biotech
Genentech
GlaxoSmithKline
The Phipps Wealth
Management Group
Novartis
Astra Zeneca
Pfizer

GOLD

Abraxis Oncology
Bristol Myers Squibb
Genomic Health
Wyeth
Roche
Millennium
Allos Therapeutics,
Inc.
ImClone

SILVER

OSI Pharmaceuticals
US Oncology

BRONZE

Genzyme

FLASCO 2009 MEETINGS:

October 3, 2009 – FLASCO Business of Oncology Summit - Tampa

November 6-7, 2009 – FLASCO Fall Meeting – Tampa Airport Marriott Hotel

March 5-6, 2010 – FLASCO Spring Meeting and Annual Session – Tampa Airport Marriott Hotel

March 26, 2010 – PA/NP Conference – Miami

FLASCO CO-SPONSORED MEETINGS:

January 16, 2010 - Clinical Breakthroughs & Challenges in Hematologic Malignancies – Grand Floridian Resort – Lake Buena Vista - For more information, call (813) 745-1247 or e-mail: Melissa.Pearson@MOFFITT.org

OTHER MEETINGS/WEBCASTS

September 10-13, 2009 - APAO Annual meeting in Boston

September 11-12, 2009 - ASH State of the Art Symposium – Chicago, IL – For more information:
<http://hematology.org/meetings/sas/index.cfm>.

September 22-25, 2009 - ACCC's 26th National Oncology Economics Conference - - Hyatt Regency Minneapolis on Nicollet Mall, 1300 Nicollet Mall, Minneapolis, MN 55403 - 612.370.1234

October 6-7, 2009 - ASCO Electronic Health Records Symposium - Harnessing the EHR: *From Incentives to Sustainability*- San Francisco Marriott Hotel - to register:
www.asco.org/ehrsymposium

Nov 1-5, 2009 - ASTRO's Annual Meeting – Chicago

November 13 - 15, 2009 - Oncology Nursing Society Fall (ONS) – Tampa

December 5-8, 2009 - ASH Annual Meeting – Ernest N. Morial Convention Center, New Orleans, LA – For more information: <http://hematology.org/meetings/2009/index.cfm>

December 10 - 13, 2009 - San Antonio Breast Cancer Symposium (SABCS) San Antonio, TX

Feb 25-27, 2010 - American College of Radiation Oncology Annual Meeting – Lake Buena Vista, FL

March 17-20, 2010 - ACCC's 36th Annual National Meeting - -Baltimore Marriott Waterfront

FLASCO Contact Info:

Dorothy Green Phillips, Executive Director - Phone: 1.813.349.4410 – Dorothy.Green@cancer.org
July 29, 2009